Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral methylene blue sustained-release tablets for detection of right-sided colonic precancerous lesions
ChiCTR2500108192Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylene blue in colon adenoma, Adenomatosis, Sessile Serrated Lesion (SSL) and 2 more, sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Right colon precancerous lesion detection rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
methylene blue
03
Conditions
colon adenomaAdenomatosisSessile Serrated Lesion (SSL)Traditional serrated adenoma (TSA)inflammatory bowel disease-associated dysplasia (IBD-D)
Beyond the preview
Go deeper on ChiCTR2500108192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108192.